Zobrazeno 1 - 10
of 70
pro vyhledávání: '"Keunchil Park"'
Autor:
Dong-Wan Kim, Sang-We Kim, D. Ross Camidge, Catherine A. Shu, Kristen A. Marrone, Xiuning Le, Collin M. Blakely, Keunchil Park, Gee-Chen Chang, Sandip Pravin Patel, Gozde Kar, Zachary A. Cooper, Ramin Samadani, Michael Pluta, Rakesh Kumar, Suresh Ramalingam
Publikováno v:
Journal of Thoracic Oncology. 18:650-656
Autor:
Hyun Ae, Jung, Miso, Kim, Hae Su, Kim, Joo-Hang, Kim, Yoon Hee, Choi, Jinhyun, Cho, Ji Hyun, Park, Keon Uk, Park, Bo Mi, Ku, Sehhoon, Park, Jong-Mu, Sun, Se-Hoon, Lee, Jin Seok, Ahn, Keunchil, Park, Myung-Ju, Ahn
Publikováno v:
Journal of Thoracic Oncology. 18:223-231
Thymic epithelial tumors (TETs) are rare but are the most common tumors of the anterior mediastinum. Platinum-based combination chemotherapy is the standard of care for such tumors and is associated with a 50% to 90% objective response rate (ORR) in
Autor:
Jiyun Lee, Jiae Koh, Hee Kyung Kim, Sungsoo Hong, Kyunga Kim, Sehhoon Park, Hyun Ae Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
Publikováno v:
Journal of Thoracic Oncology. 17:900-908
Vascular endothelial growth factor promotes an immunosuppressive tumor microenvironment that can be reverted by an antiangiogenic therapy. This two-stage, phase 2 study aimed to determine the treatment efficacy of adding bevacizumab to atezolizumab i
Autor:
Fabrice Barlesi, C. Matheny, Julien Mazieres, Diego Cortinovis, Wei Yu, Marcus Ballinger, Keunchil Park, David R. Gandara, S. Gadgeel, Achim Rittmeyer, Toyoaki Hida
Publikováno v:
Journal of Thoracic Oncology. 16:140-150
Introduction The phase 2 POPLAR and phase 3 OAK studies of the anti–programmed death-ligand 1 (PD-L1) immunotherapy atezolizumab in patients with previously treated advanced NSCLC revealed significant improvements in survival versus docetaxel (p =
Autor:
John D. Minna, William D. Travis, Neal Ready, David MacPherson, Charles M. Rudin, Matthew G. Oser, Caroline Dive, Ramaswamy Govindan, Giorgio V. Scagliotti, Christine L. Hann, Keunchil Park, Huanhuan Joyce Chen, Elisabeth Brambilla, Julien Sage, Kwon-Sik Park, Martin L. Sos, Jillian B. Daigneault, Taofeek K. Owonikoko, Camilla L. Christensen, Sumin Kang, Young Seok Ju, Jane E. Johnson, Trudy G. Oliver, Hua Zhang, Kate D. Sutherland, Benjamin H. Lok, Kwok-Kin Wong, Christine M. Lovly, John T. Poirier, David G. McFadden, Yves Pommier, David P. Carbone, Ignacio I. Wistuba, Vito Quaranta, Matthew D. Hellmann, Mark A. Krasnow, Jonathan M. Lehman, Sarah J. Wait, Christopher R. Vakoc, Lauren Averett Byers, Se-Hoon Lee, James L. Lee, Leora Horn, Anna F. Farago, Julie George, Jacinta Wiens, Anton Berns
Publikováno v:
Journal of Thoracic Oncology. 15:520-540
The outcomes of patients with SCLC have not yet been substantially impacted by the revolution in precision oncology, primarily owing to a paucity of genetic alterations in actionable driver oncogenes. Nevertheless, systemic therapies that include imm
Autor:
Keunchil Park, Woong-Yang Park, Sehhoon Park, Hayoon Lee, Myung-Ju Ahn, Jin Seok Ahn, Jong-Mu Sun, Se-Hoon Lee, Boram Lee
Publikováno v:
Journal of Thoracic Oncology. 14:1640-1650
Impairment in DNA damage response and repair (DDR) pathway is known as a predictive biomarker of platinum sensitivity. Recently, DDR alteration is re-emphasized as a predictive biomarker of immune checkpoint inhibitor due to its positive correlation
Autor:
Sook J. Lee, Youjin Kim, Kyunga Kim, Se-Hoon Lee, Myung-Ju Ahn, Hong Sook Kim, Jin Seok Ahn, Sungjun Hong, Sang Won Seo, Jong-Mu Sun, Chu Hyun Kim, Keunchil Park, Ho Yun Lee, Hongui Cha
Publikováno v:
Journal of Thoracic Oncology. 14:1608-1618
Introduction Hyperprogressive disease (HPD), characterized by accelerated tumor progression, has been proposed as a new pattern of progression after immune checkpoint inhibitor (ICI) treatment. The aim of this study was to describe the characteristic
Autor:
Myung-Ju Ahn, Yoon-La Choi, Se-Hoon Lee, Jong-Mu Sun, Youjin Kim, Boram Lee, Keunchil Park, Joon Ho Shim, Woong-Yang Park, Jin Seok Ahn
Publikováno v:
Journal of Thoracic Oncology. 14:193-202
EGFR-mutant NSCLC displays diverse outcomes to tyrosine kinase inhibitor (TKI) treatment. Because co-occurring genomic alterations might describe different biological subsets of patients with this cancer, exploring co-occurring genomic alterations th
Autor:
Yoon-La Choi, Byoung Chul Cho, Myung-Ju Ahn, Beung Chul Ahn, Sung Won Lim, Jong Mu Sun, Se-Hoon Lee, Keunchil Park, Jin Seok Ahn, Sehhoon Park, Min Hee Hong, Hye Ryun Kim
Publikováno v:
Journal of Thoracic Oncology. 13:1373-1382
Introduction ROS1-rearranged NSCLC is classified as a distinct molecular subset of NSCLC with a therapeutic target. ROS1 rearrangement is most often identified in never-smokers with adenocarcinoma and EGFR and ALK receptor tyrosine kinase gene (ALK)
Autor:
Keunchil Park, Egbert F. Smit, Christos Chouaid, Dong Wan Kim, Emin Avsar, Edward B. Garon, Enriqueta Felip, Leena Gandhi, Lecia V. Sequist, Paal Brunsvig, Enric Carcereny, Harry J.M. Groen, Benjamin Besse, Quincy Chu, Mikhail Akimov, Sebastian Szpakowski, Sang-We Kim, Fabrice Barlesi
Publikováno v:
Felip, E, Barlesi, F, Besse, B, Chu, Q, Gandhi, L, Kim, S-W, Carcereny, E, Sequist, L V, Brunsvig, P, Chouaid, C, Smit, E F, Groen, H J M, Kim, D-W, Park, K, Avsar, E, Szpakowski, S, Akimov, M & Garon, E B 2018, ' Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non–Small Cell Lung Cancer ', Journal of Thoracic Oncology, vol. 13, no. 4, pp. 576-584 . https://doi.org/10.1016/j.jtho.2017.11.131
Journal of Thoracic Oncology, 13(4), 576-584. ELSEVIER SCIENCE INC
Journal of Thoracic Oncology, 13(4), 576-584. International Association for the Study of Lung Cancer
Journal of Thoracic Oncology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Journal of Thoracic Oncology, 13(4), 576-584. ELSEVIER SCIENCE INC
Journal of Thoracic Oncology, 13(4), 576-584. International Association for the Study of Lung Cancer
Journal of Thoracic Oncology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Introduction: In this phase 2 study, we evaluated the activity of AUY922 in pretreated patients with stage IV NSCLC. Methods: Patients with advanced NSCLC were divided into molecularly defined strata based on mutations in the EGFR gene, the ALK recep